Rubraca Tablet, Film Coated
NDC Package 82154-0785-1
Package Information
Rubraca (rucaparib) tablets is a medication used to treat certain cancers (such as ovarian, fallopian tube, peritoneal, prostate cancer). This formulation utilizes a tablet, film coated delivery system. Marketed by Pharmaand Gmbh, this product is identified by NDC 82154-0785 and is authorized under FDA application NDA209115.
Identification & Billing
- RxCUI: 1862584 - rucaparib 300 MG Oral Tablet
- RxCUI: 1862584 - rucaparib (as rucaparib camsylate) 300 MG Oral Tablet
- RxCUI: 1862590 - Rubraca 300 MG Oral Tablet
- RxCUI: 1862590 - rucaparib 300 MG Oral Tablet [Rubraca]
- RxCUI: 1862590 - Rubraca (as rucaparib camisylate) 300 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82154 - Pharmaand Gmbh
- 82154-0785 - Rubraca
- 82154-0785-1 - 60 TABLET, FILM COATED in 1 BOTTLE
- 82154-0785 - Rubraca
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82154-0785-1 identifies a specific commercial package of 60 tablet, film coated in 1 bottle of Rubraca, a human prescription drug labeled by Pharmaand Gmbh. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This tablet, film coated is formulated for oral use and contains rucaparib camsylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pharmaand Gmbh on December 19, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain cancers (such as ovarian, fallopian tube, peritoneal, prostate cancer). It works by slowing or stopping the growth of cancer cells.
How is this Pharmaand Gmbh product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82154078501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.